Earnings Per Share (EPS) of $2.28, beating the estimated $2.12.
Revenue of approximately $13.23 billion, slightly below the estimated $13.81 billion.
Increased 2025 financial outlook following a 23% surge in core operating profit.

Novartis AG, listed as NYSE:NVS, is a leading global healthcare company known for its innovative pharmaceuticals. On April 29, 2025, NVS reported earnings per share of $2.28, surpassing the estimated $2.12. Despite this, the company generated revenue of approximately $13.23 billion, slightly below the estimated $13.81 billion.

Novartis has increased its 2025 financial outlook following a significant rise in its core operating profit, which surged by 23% year-over-year. This impressive growth was driven by strong demand for the company’s key drugs, including Kisqali, Kesimpta, and Leqvio. The positive financial performance has led Novartis to adjust its guidance upwards, reflecting confidence in its continued success.

The company’s financial metrics provide further insight into its market position. Novartis has a price-to-earnings (P/E) ratio of approximately 18.74, indicating the market’s valuation of its earnings. The price-to-sales ratio stands at about 4.36, reflecting the value investors are placing on its sales. Additionally, the enterprise value to sales ratio is around 4.74, suggesting how the market values the company’s total worth relative to its sales.

Novartis’s financial health is also highlighted by its enterprise value to operating cash flow ratio of approximately 13.75, providing insight into the company’s cash flow efficiency. The earnings yield of 5.34% offers a perspective on the return on investment. With a debt-to-equity ratio of 0.71, Novartis maintains a moderate level of debt relative to equity, indicating a balanced financial structure. The current ratio of about 1.04 suggests that the company has a slightly higher level of current assets compared to its current liabilities, which is a positive indicator of short-term financial health.